Conclusion
tumor
LIVER CANCER, TUMOR
In summary, TACE combined with TKI and camrelizumab has longer progression-free survival benefits and a high tumor control rate with a manageable safety profile in the treatment of advanced liver cancer. Thus, the combination regimen could provide a new treatment option for this patient population.